SANA
NASDAQ · Biotechnology
Sana Biotechnology Inc
$2.56
+0.12 (+4.92%)
Open$2.55
Previous Close$2.44
Day High$2.62
Day Low$2.46
52W High$5.58
52W Low$2.22
Volume—
Avg Volume2.65M
Market Cap769.36M
P/E Ratio—
EPS$-0.76
SectorBiotechnology
Analyst Ratings
Strong Buy
15 analysts
Price Target
+1,465.6% upside
Current
$2.56
$2.56
Target
$40.08
$40.08
$23.55
$40.08 avg
$57.48
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 204.77M | 187.81M | 190.12M |
| Net Income | 17.06M | 14.80M | 14.99M |
| Profit Margin | 8.3% | 7.9% | 7.9% |
| EBITDA | 24.96M | 25.10M | 25.01M |
| Free Cash Flow | 20.72M | 16.56M | 17.82M |
| Rev Growth | +11.7% | +19.4% | -6.7% |
| Debt/Equity | 0.32 | 0.27 | 0.29 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $288.24 | -2.24% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $460.28 | -3.80% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $167.57 | -3.96% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $542.50 | -1.19% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $902.90 | -2.98% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.66 | -2.74% | 28.8 | 23.28B |